An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to European sourced Valtrex® Tablets in normal, healthy subjects under fasting conditions.

2024-516184-87-00 Protocol HY-029-04 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 18 Oct 2024 · End 3 Nov 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol HY-029-04

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 30
Countries 1
Sites 1

not applicable (submitted trial is a bioavailability study in healthy subjects)

Key facts

Sponsor
Dermax
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17], Diseases [C] - Virus Diseases [C02]
Trial duration
18 Oct 2024 → 3 Nov 2024
Decision date (initial)
2024-09-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

not applicable (submitted trial is a bioavailability study in healthy subjects)

VersionLevelCodeTermSystem organ class
20.0 HLGT 10047438 Viral infectious disorders 10021881

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Dermax

Sponsor organisation
Dermax
Address
Boulev. De Patience Et Beajonc 3 Box 1
City
Liege
Postcode
4000
Country
Belgium

Scientific contact point

Organisation
Dermax
Contact name
Christophe Lyssens

Public contact point

Organisation
Dermax
Contact name
Christophe Lyssens

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 30 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinical Unit, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-10-18 2024-11-03 2024-10-18 2024-10-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-19 Czechia Acceptable
2024-09-06
2024-09-13